Investigational, once-weekly insulin icodec showed comparable efficacy and safety to once-daily insulin glargine U100 in phase 2 trial

PLAINSBORO, N.J., June 14, 2020 /PRNewswire/ -- Today, Novo Nordisk announced results from a phase 2 clinical trial of investigational insulin icodec, a once-weekly basal insulin analog. In the trial, adults with type 2 diabetes randomized to once-weekly insulin icodec achieved similar...

from PR Newswire: https://ift.tt/30EXiXK